Lucerastat
Sponsors
Idorsia Pharmaceuticals Ltd.
Conditions
Fabry DiseaseFabry diseaseHealthy Subjects
Phase 1
A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease
CompletedNCT02930655
Start: 2015-02-01End: 2016-02-01Updated: 2018-07-10
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lucerastat (CDP923) After Multiple Dosing in Healthy Subjects
CompletedNCT02944474
Start: 2003-12-31End: 2004-05-31Updated: 2025-05-02
A Study to Assess the Safety and Pharmacokinetics of Lucerastat (OGT 923) in Healthy Subjects
CompletedNCT02944487
Start: 2002-10-31End: 2002-12-31Updated: 2025-05-01
Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects
CompletedNCT03380455
Start: 2018-01-09End: 2018-01-29Updated: 2022-06-02
Phase 3
Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease
CompletedNCT03425539
Start: 2018-06-21End: 2021-09-02Updated: 2024-08-09
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease
Active, not recruitingNCT03737214
Start: 2018-12-18End: 2029-11-01Target: 107Updated: 2026-08-31
A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease.
Active, not recruitingCTIS2024-513884-20-00
Start: 2019-03-13Target: 45Updated: 2025-11-20
A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease
Not yet recruitingNCT07778667
Start: 2026-09-01End: 2029-03-01Target: 16Updated: 2026-08-21
A multicenter, open-label, single-arm, baseline-controlled trial to assess the efficacy and safety of lucerastat in treatment-naïve/pseudo-naïve adult male participants with Fabry disease
Not yet recruitingCTIS2026-525207-27-00
Target: 8Updated: 2026-08-27